Jun 27, 2022 7:00am EDT Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication
Jun 22, 2022 7:00am EDT Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock
Jun 21, 2022 7:00am EDT Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia
Jun 16, 2022 7:00am EDT Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts
Jun 9, 2022 7:00am EDT Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress
Jun 8, 2022 4:05pm EDT Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology
Jun 8, 2022 7:00am EDT Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology
Jun 6, 2022 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention
Jun 2, 2022 7:00am EDT Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jun 1, 2022 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology
